Baird Downgrades VistaGen Therapeutics (VTGN) to Neutral
Tweet
Share
E-mailGet Alerts VTGN Hot Sheet
Price: $0.27 --0%
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Baird analyst Brian Skorney downgraded VistaGen Therapeutics (NASDAQ: VTGN) from Outperform to Neutral with a price target of $0.25.
For an analyst ratings summary and ratings history on VistaGen Therapeutics click here. For more ratings news on VistaGen Therapeutics click here.
Shares of VistaGen Therapeutics closed at $1.07 yesterday.
You May Also Be Interested In
- Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
- Wedbush Downgrades Globant S.A. (GLOB) to Neutral on balanced risk/reward
- Citizens Downgrades Accelerant Holdings (ARX) to Market Perform
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
